

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A contraceptive and/or HRT kit comprising a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15.
2. (Canceled)
3. (Previously Presented) The kit according to claim 1, further comprising a contraceptively and/or therapeutically effective amount of an androgen ester.
4. (Previously Presented) The kit according to claim 3, wherein the androgen ester is MENT undecanoate.
5. (Currently Amended) The kit ~~according~~ according to claim 4, wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-400 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 25-200 mg.
6. (Previously Presented) The kit according to claim 5, wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-200 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50-100 mg.
7. (Previously Presented) The kit according to claim 6, wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 100 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50 mg.
8. (Previously Presented) The kit according to claim 1, further comprising a contraceptively and/or therapeutically effective amount of an estrogen.
- 9-17. (Canceled).
18. (Previously Presented) A method of contraception and/or HRT, comprising;

administering to a subject a contraceptively and/or therapeutically effective amount of a long acting etonogestrel ester with a fatty-chain length of C7-C15.

19. (Canceled)

20. (Previously Presented) The method according to claim 18, wherein a contraceptively and/or therapeutically effective amount of a long-acting androgen ester is administered in conjunction with the etonogestrel ester.

21. (Previously Presented) The method according to claim 20, wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate and the androgen ester is MENT undecanoate.

22. (Previously Presented) The method according to claim 21, wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-400 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 25-200 mg.

23. (Previously Presented) The method according to claim 22, wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-200 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50-100 mg.

24. (Previously Presented) The method according to claim 23, wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 100 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50 mg.

25. (Previously Presented) The method according to claim 18, wherein a contraceptively and/or therapeutically effective amount of an estrogen is administered in conjunction with the etonogestrel ester.

26-28. (Canceled).

29. (Previously Presented) A method of treating and/or preventing a female gynecological disorder, comprising:

administering to a female subject a therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15 effective to treat and/or prevent the disorder.

30. (Canceled)

31. (Previously Presented) The method according to claim 29, wherein the female gynecological disorder is selected from the group consisting of endometriosis, menorrhagia, menometrorrhagia, pre-menstrual syndrome and dysmenorrhoea.